Urban Lundberg

This inventor holds 21 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Vaccine Development. Top assignees: Valneva Austria Gmbh, Valneva Se, Intercell Ag. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Urban Lundberg. Retrieved from https://idiyas.com/inventor/urban-lundberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 15)

% Patents Active = 81.0

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 8 (Patent Applications = 18)

Average Co-Inventor Count = 4.9

ph-index = 6

Forward Citations = 67(Granted Patents)

Location History:

Dresden, DE (2012)
Vienna, AT (2012)
Pressbaum, AT (2012 - 2024)

Company Filing History:

Biopharma Credit Plc, as Collateral Agent

patents

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Chikungunya Virus

OspA Polypeptides

Subunit Vaccine

Immunogenic Compositions

Respiratory Tract Infection

Multivalent Vaccines

Pharmaceutical Compositions

Vaccine Production

Fusion Proteins

Medical Use

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12564625 - METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NSP3 (2026-03-03),

2. 12514912 - COMPOSITIONS COMPRISING THREE OSPA FUSION PROTEINS FOR MEDICAL USE (2026-01-06),

3. 12331084 - Multivalent OspA polypeptides and methods and uses relating thereto (2025-06-17),

4. 12195501 - Mutant fragments of OspA and methods and uses relating thereto (2025-01-14),

5. 12162909 - Subunit vaccine for treatment or prevention of a respiratory tract infection (2024-12-10),

6. 12162907 - Subunit vaccine for treatment or prevention of a respiratory tract infection (2024-12-10),

7. 12018054 - Multivalent OspA polypeptides and methods and uses relating thereto (2024-06-25),

8. 12011477 - Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3 (2024-06-18),

9. 11572392 - Mutant fragments of OspA and methods and uses relating thereto (2023-02-07),

10. 11466058 - Mutant fragments of OspA and methods and uses relating thereto (2022-10-11),

11. 11357846 - Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Delta5NP3 (2022-06-14),

12. 11208439 - Mutant fragments of OspA and methods and uses relating thereto (2021-12-28),

13. 10766931 - Mutant fragments of OspA and methods and uses relating thereto (2020-09-08),

14. 10544194 - Mutant fragments of OspA and methods and uses relating thereto (2020-01-28),

15. 9975927 - Mutant fragments of OspA and methods and uses relating thereto (2018-05-22),

Title: Celebrating the Innovations of Urban Lundberg

Introduction

Urban Lundberg, an innovative inventor based in Pressbaum, Austria, has made significant contributions to the field of biotechnology. With an impressive portfolio of 18 patents, Lundberg stands out as a thought leader in developing advanced medical technologies. His work primarily focuses on vaccines and therapeutic methods, addressing critical health challenges.

Latest Patents

Among his latest inventions, one notable patent includes "Mutant fragments of OspA and methods and uses relating thereto." This invention pertains to a polypeptide that contains a mutant fragment of an outer surface protein A (OspA). It encompasses a nucleic acid coding for this polypeptide, as well as a pharmaceutical composition intended to treat or prevent infections. Furthermore, it outlines a method for immunizing subjects, showcasing Lundberg's commitment to enhancing medical treatment.

Another significant patent is a "Subunit vaccine for treatment or prevention of a respiratory tract infection." This innovation relates to modified human Metapneumovirus (hMPV) F proteins that are stabilized in the pre-fusion conformation, thereby serving as potential vaccine candidates. These inventions highlight Lundberg's versatility and dedication to combatting respiratory diseases.

Career Highlights

Urban Lundberg has been associated with Valneva Austria GmbH and Valneva SE, where he has honed his skills in biopharmaceutical innovation. His experience within these companies has played a pivotal role in shaping his career as an inventive force in the biotechnology landscape.

Collaborations

Throughout his career, Lundberg has collaborated with esteemed colleagues such as Andreas Meinke and Wolfgang Schüler. These partnerships have further propelled his research and development endeavors, resulting in groundbreaking inventions that contribute to public health.

Conclusion

Urban Lundberg exemplifies the spirit of innovation in the biotechnology sector. His passion for creating solutions to medical challenges through his patented inventions signifies his role as a vital contributor to the field. As he continues to push the boundaries of what is possible, Lundberg's legacy will undoubtedly inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.